619 related articles for article (PubMed ID: 24986690)
1. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
Rumi E; Pietra D; Pascutto C; Guglielmelli P; Martínez-Trillos A; Casetti I; Colomer D; Pieri L; Pratcorona M; Rotunno G; Sant'Antonio E; Bellini M; Cavalloni C; Mannarelli C; Milanesi C; Boveri E; Ferretti V; Astori C; Rosti V; Cervantes F; Barosi G; Vannucchi AM; Cazzola M;
Blood; 2014 Aug; 124(7):1062-9. PubMed ID: 24986690
[TBL] [Abstract][Full Text] [Related]
2. The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.
Kuo MC; Lin TH; Sun CF; Lin TL; Wu JH; Wang PN; Huang YJ; Chang H; Huang TY; Shih LY
J Clin Pathol; 2018 Jun; 71(6):514-521. PubMed ID: 29203554
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis].
Xu ZF; Li B; Liu JQ; Li Y; Ai XF; Zhang PH; Qin TJ; Zhang Y; Wang JY; Xu JQ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):576-80. PubMed ID: 27535857
[TBL] [Abstract][Full Text] [Related]
4. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
[TBL] [Abstract][Full Text] [Related]
5. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
Tefferi A; Lasho TL; Finke CM; Knudson RA; Ketterling R; Hanson CH; Maffioli M; Caramazza D; Passamonti F; Pardanani A
Leukemia; 2014 Jul; 28(7):1472-7. PubMed ID: 24402162
[TBL] [Abstract][Full Text] [Related]
6. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
Alshemmari SH; Rajan R; Emadi A
Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
8. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
Elala YC; Lasho TL; Gangat N; Finke C; Barraco D; Haider M; Abou Hussein AK; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2016 May; 91(5):503-6. PubMed ID: 26890983
[TBL] [Abstract][Full Text] [Related]
9. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
10. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
11. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
12. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.
Tefferi A; Nicolosi M; Mudireddy M; Szuber N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Mannarelli C; Fanelli T; Guglielmelli P; Vannucchi AM
Am J Hematol; 2018 Mar; 93(3):348-355. PubMed ID: 29164670
[TBL] [Abstract][Full Text] [Related]
13. Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center.
Palova M; Szotkowski T; Hlusi A; Indrak K; Navratilova J; Divoka M; Papajik T
Neoplasma; 2018; 65(2):296-303. PubMed ID: 29534592
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
[TBL] [Abstract][Full Text] [Related]
15. JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.
Wang J; Zhang B; Chen B; Zhou RF; Zhang QG; Li J; Yang YG; Zhou M; Shao XY; Xu Y; Xu XH; Ouyang J; Xu J; Ye Q
Hematology; 2017 Apr; 22(3):145-148. PubMed ID: 27875935
[TBL] [Abstract][Full Text] [Related]
16. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Rumi E; Pietra D; Ferretti V; Klampfl T; Harutyunyan AS; Milosevic JD; Them NC; Berg T; Elena C; Casetti IC; Milanesi C; Sant'antonio E; Bellini M; Fugazza E; Renna MC; Boveri E; Astori C; Pascutto C; Kralovics R; Cazzola M;
Blood; 2014 Mar; 123(10):1544-51. PubMed ID: 24366362
[TBL] [Abstract][Full Text] [Related]
17. Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations.
Li N; Yao QM; Gale RP; Li JL; Li LD; Zhao XS; Jiang H; Jiang Q; Jiang B; Shi HX; Chen SS; Liu KY; Huang XJ; Ruan GR
Leuk Res; 2015 May; 39(5):510-4. PubMed ID: 25746303
[TBL] [Abstract][Full Text] [Related]
18. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
Tefferi A; Guglielmelli P; Larson DR; Finke C; Wassie EA; Pieri L; Gangat N; Fjerza R; Belachew AA; Lasho TL; Ketterling RP; Hanson CA; Rambaldi A; Finazzi G; Thiele J; Barbui T; Pardanani A; Vannucchi AM
Blood; 2014 Oct; 124(16):2507-13; quiz 2615. PubMed ID: 25037629
[TBL] [Abstract][Full Text] [Related]
20. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.
Usseglio F; Beaufils N; Calleja A; Raynaud S; Gabert J
J Mol Diagn; 2017 Jan; 19(1):92-98. PubMed ID: 27855276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
